Secondary analysis of FINEARTS-HF (5,988 patients with HF and LVEF ≥40%): one-third had an HFpEF-ABA score <75%; higher scores were associated with more HF events, rising steeply above ~75%, and finerenone's benefit over placebo was consistent across scores.
Secondary analysisn = 5,988
Ono et al. HFpEF-ABA Score and Finerenone in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: Insights From the FINEARTS-HF Trial